Cisatracurium Infusion Dosing
For adult critically ill patients, initiate cisatracurium with a loading dose of 0.1-0.2 mg/kg followed by a continuous infusion starting at 2.5-3 mcg/kg/min, with no dose adjustment needed for elderly patients or those with renal or hepatic dysfunction. 1, 2
Loading Dose
Administer 0.1-0.2 mg/kg IV bolus over 5-10 seconds 1, 2:
- 0.1 mg/kg produces paralysis in approximately 2.5 minutes with clinically effective blockade lasting ~55 minutes
- 0.2 mg/kg produces paralysis in approximately 1.5 minutes with clinically effective blockade lasting ~61 minutes
- Higher doses (0.15-0.2 mg/kg) provide more reliable excellent intubation conditions 2
Maintenance Infusion
Start at 2.5-3 mcg/kg/min and titrate to clinical effect or train-of-four (TOF) monitoring 1:
- Clinical trials have used infusion rates ranging from 2-8 mcg/kg/min 1
- For ARDS patients specifically, the ACURASYS trial used a fixed dose of 15 mg bolus followed by 37.5 mg/hour (approximately 5 mcg/kg/min for a 75 kg patient) for 48 hours 3, 4
- Median stable dose in ARDS patients is approximately 2.8 mcg/kg/min (range 2.0-3.1) 5
Special Populations
Elderly Patients (≥65 years)
No dose adjustment required 1, 6, 2:
- Onset time is approximately 1 minute slower (297 vs 199 seconds with 0.15 mg/kg) 7
- Duration of action is slightly longer (89 vs 77 minutes) but clinically insignificant 7
- Use the same loading dose; consider extending the interval between administration and intubation attempt by 1-2 minutes 1
- Plasma clearance remains unchanged; slightly larger volume of distribution does not warrant dose reduction 2
Renal Dysfunction/Failure
No dose adjustment required 1, 6, 2:
- Cisatracurium undergoes organ-independent Hofmann elimination (77% of clearance) 2, 8
- Pharmacokinetics and pharmacodynamics are similar in patients with end-stage renal disease compared to healthy patients 2
- Onset time may be approximately 1 minute slower 2
- Recovery profile remains unchanged 1, 2
- Important caveat: Patients with acute kidney injury may require 31% lower infusion rates to maintain adequate neuromuscular blockade 5
Hepatic Dysfunction/Failure
No dose adjustment required 1, 6, 2:
- Pharmacokinetics in liver transplant patients show slightly larger volume of distribution but proportionally higher clearance, resulting in unchanged elimination half-life 2
- Onset time may be approximately 1 minute faster in liver transplant patients 2
- Duration of blockade is not affected by hepatic dysfunction 1
Critical Monitoring Considerations
Train-of-Four (TOF) monitoring is strongly recommended to optimize dosing and prevent excessive neuromuscular blockade 1, 3:
- Target TOF count of 1-2 twitches out of 4 for adequate paralysis
- Adjust infusion rate based on TOF response rather than using fixed high doses
- TOF-guided dosing reduces cisatracurium consumption by approximately 40% compared to fixed dosing (612 mg vs 1034 mg cumulative dose) 9
- Recovery to TOF ratio ≥0.7 occurs within 34-85 minutes after discontinuation, independent of organ function 1
Common Pitfalls to Avoid
Do not reduce initial loading dose in elderly or organ dysfunction patients—this delays onset without providing benefit 6, 2
Do not use fixed high-dose protocols (e.g., 5 mcg/kg/min continuously) without TOF monitoring—this increases drug consumption and may worsen outcomes compared to titrated dosing 9
Ensure adequate sedation and analgesia before and during neuromuscular blockade—cisatracurium has no analgesic or amnestic properties 1
Monitor for acute kidney injury during infusion—presence of AKI may necessitate 30% reduction in infusion rate 5
For ARDS patients with severe hypoxemia (PaO2/FiO2 <150), consider the evidence-based protocol of 15 mg bolus + 37.5 mg/hour for 48 hours, which has mortality benefit 3, 4